var data={"title":"Recombinant hepatitis B vaccine (non-adjuvanted): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Recombinant hepatitis B vaccine (non-adjuvanted): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6311?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=recombinant-hepatitis-b-vaccine-non-adjuvanted-drug-information\" class=\"drug drug_general\">see &quot;Recombinant hepatitis B vaccine (non-adjuvanted): Drug information&quot;</a> and <a href=\"topic.htm?path=recombinant-hepatitis-b-vaccine-non-adjuvanted-patient-drug-information\" class=\"drug drug_patient\">see &quot;Recombinant hepatitis B vaccine (non-adjuvanted): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178984\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Engerix-B;</li>\n      <li>Recombivax HB</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178985\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Engerix-B;</li>\n      <li>Recombivax HB</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059212\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Inactivated Virus</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442600\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">Although hepatitis B vaccine products differ by concentration (mcg/mL), when dosed in terms of volume (mL), the equivalent dose is the same between products (ie, 0.5 mL of Recombivax-HB is equivalent to 0.5 mL of Engerix-B). Combination vaccines should not be used for the &quot;birth&quot; dose but may be used to complete the immunization series after the infant is 6 weeks of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization: Recombivax-HB, Engerix-B (Pediatric/Adolescent formulation):</b> IM: 0.5 mL per dose for a total of 3 doses; see the following for administration schedule:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CDC (ACIP) Recommendations (AAP 2017; ACIP [Robinson 2017]; CDC/ACIP [Mast 2005]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Neonates born to HBsAg-<b>positive</b> mothers: </i>Administer first dose within the first 12 hours of birth, even if premature and regardless of birth weight (hepatitis immune globulin should also be administered at the same time/different site); <b>Note:</b> Due to possible decreased immunogenicity, premature neonates &lt;2 kg should receive 4 total doses at 0, 1, 2 to 3, and 6 to 7 months of chronological age.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Neonates born to HBsAg-</i>\n      <b>\n        <i>negative</i></b>\n      <i> mothers:</i> First dose should be given within 24 hours of birth for neonates weighing &ge;2 kg. Premature neonates weighing &lt;2 kg may have the initial dose deferred up to 30 days of chronological age or at hospital discharge.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Neonates born to mothers with unknown HBsAg status at birth:</i> Administer first dose within 12 hours of birth even if premature and regardless of birth weight, second dose following 1 to 2 months later; if HBsAg test is positive, the neonate should receive hepatitis immune globulin as soon as possible (no later than 12 hours of age if &lt;2 kg or age 1 week if &ge;2 kg). <b>Note:</b> Due to possible decreased immunogenicity, premature neonates &lt;2 kg, who received an initial dose within 12 hours of birth, should receive 4 total doses at 0, 1, 2 to 3, and 6 to 7 months of chronological age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neonates with recent exposure to the virus or certain travelers to high-risk areas:</b> Engerix-B (Pediatric/Adolescent formulation): IM: 0.5 mL per dose for 4 doses given at 0, 1, 2, and 12 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059206\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=recombinant-hepatitis-b-vaccine-non-adjuvanted-drug-information\" class=\"drug drug_general\">see &quot;Recombinant hepatitis B vaccine (non-adjuvanted): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Although hepatitis B vaccine products differ by concentration (mcg/mL), when dosed in terms of volume (mL), the equivalent dose is the same between products (ie, 0.5 mL of Recombivax-HB is equivalent to 0.5 mL of Engerix-B). Combination vaccines may be used to complete the immunization series after the infant is 6 weeks of age. Please see combination vaccine monographs for dose and schedule details. Vaccines from different manufacturers are interchangeable during an immunization series with the exception of an adolescent (11 to 15 years) 2-dose Recombivax-HB regimen (CDC/ACIP [Mast 2005]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CDC (ACIP) recommendations (CDC/ACIP [Mast 2005]; ACIP [Robinson 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: Recombivax-HB, Engerix-B (Pediatric/Adolescent formulation): IM: 0.5 mL per dose for a total of 3 doses given as follows: Ideally first dose is given at birth, the second dose is given at 1 to 2 months of age, and a final third dose at 6 months up to 18 months of age; minimum age for the final (third) dose is 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Infants born of HBsAg-<b>positive</b> mothers:</i> First dose should be given within the first 12 hours of birth, even if premature and regardless of birth weight (hepatitis immune globulin should also be administered at the same time/different site); the second dose is administered at 1 to 2 months of age and the third dose at 6 months of age; anti-HBs and HBsAg levels should be checked at 9 to 18 months of age (eg, next well child visit after series completion) or 1 to 2 months after completion of the hepatitis B vaccine series if delayed. If HBsAg is negative and anti-HBs levels &lt;10 milliunits/mL, reimmunize with 3 doses 2 months apart and reassess. <b>Note:</b> Due to possible decreased immunogenicity, premature neonates &lt;2 kg should receive 4 total doses at 0, 1, 2 to 3, and 6 to 7 months of chronological age.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Infants born of HBsAg-</i>\n      <b>\n        <i>negative</i></b>\n      <i> mothers:</i> First dose should be given within 24 hours of birth; another dose is given 1 to 2 months later and a final dose at 6 to 18 months of age; 4 total doses of vaccine may be given if a &quot;birth dose&quot; is administered and a combination vaccine is used to complete the series. If &quot;birth dose&quot; not received, then full-term neonates should begin vaccine series as soon as feasible. <b>Note:</b> Premature neonates &lt;2 kg may have the initial dose deferred up to 30 days of chronological age or at hospital discharge.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Infants born of mothers whose HBsAg status is <b>unknown</b> at birth:</i> First dose given within 12 hours of birth even if premature and regardless of birth weight, second dose following 1 to 2 months later; the third dose at 6 months of age; if the mother's blood HBsAg test is positive, the infant should receive hepatitis immune globulin as soon as possible (no later than 12 hours of age if &lt;2 kg or age 1 week if &ge;2 kg). <b>Note:</b> Due to possible decreased immunogenicity, premature neonates &lt;2 kg who received an initial dose within 12 hours of birth, should receive 4 total doses at 0, 1, 2 to 3, and 6 to 7 months of chronological age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catch-up immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CDC (ACIP) recommendations (ACIP [Robinson 2017]): <b>Note:</b> Do not restart the series. If doses have been given, begin the below schedule at the applicable dose number.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants &ge;4 months, Children, and Adolescents: Recombivax-HB, Engerix-B (Pediatric/Adolescent formulation): IM: 0.5 mL per dose for 3 total doses</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">First dose given on the elected date</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Second dose given at least 4 weeks after the first dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Third dose given at least 8 weeks after the second dose and at least 16 weeks after the first dose; minimum age for the final (third) dose is 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate regimen: Adolescents 11 to 15 years: Recombivax HB (Adult formulation): IM: 1 mL per dose for 2 doses; first dose given on the elected date, second dose given 4 to 6 months later if patient still &le;15 years.<b> Note:</b> Refer to most recent CDC guideline for other options. Manufacturer's labeling may include alternate immunization schedules.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bombings or similar mass casualty events:</b> IM: In persons without a reliable history of vaccination against hepatitis B and who have no known contraindications to the vaccine, vaccination should begin within 24 hours (but no later than 7 days) following the event (CDC [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Adult formulations of hepatitis B vaccine products differ by concentration (mcg/mL), but when dosed in terms of volume (mL), the dose of Engerix-B and Recombivax HB are the same (both 1 mL).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompetent adults: IM: 1 mL/dose (adult formulation) for 3 total doses administered at 0, 1, and 6 months.<b> Note:</b> Refer to CDC guideline (Mast 2006) for other options. Manufacturer's labeling may include alternate immunization schedules.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults with immunocompromising conditions (ACIP [Kim 2017]): IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Engerix-B 20 mcg/mL: Administer 2 mL per dose at 0, 1, 2, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Recombivax HB 40 mcg/mL: Administer 1 mL per dose at 0, 1, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bombings or similar mass casualty events:</b> IM: In persons without a reliable history of vaccination against HepB and who have no known contraindications to the vaccine, vaccination should begin within 24 hours (but no later than 7 days) following the event (CDC [Chapman 2008]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postexposure management of health care personnel (HCP)</b> (CDC [Schillie 2013]): IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Documented vaccine responder:</i> If the HCP has prior documentation of &ge;3 doses of a hepatitis B vaccine and a postvaccination anti-HBs &ge;10 milliunits/mL, then additional hepatitis B vaccine is not needed, regardless of the patient's HBsAg status. HCP is considered seroprotected.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Unvaccinated or incompletely vaccinated:</i> The primary vaccination series should be completed regardless of the source patient's HBsAg status. If the source patient is HBsAg positive or their status is unknown, 1 dose of hepatitis B vaccine and 1 dose of hepatitis B immunoglobulin (HBIG) should be administered as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Vaccinated with 3 doses of hepatitis B vaccine but postvaccination anti-HBs status is unknown:</i> Test HCP for anti-HBs. If anti-HBs &ge;10 milliunits/mL, additional hepatitis B vaccine is not needed. If anti-HBs &lt;10 milliunits/mL, initiate revaccination by administering a single dose of the vaccine and retesting for anti-HBs in 1 to 2 months; if needed, 2 additional doses may be given and then retest anti-HBs level. Alternately, administer 3 consecutive doses of the vaccine and then retest anti-HBs level. Minimum dosing intervals are 4 weeks between doses 1 and 2 and 8 weeks between doses 2 and 3; maximum total of 6 doses of hepatitis B vaccine (including the original series). If the source patient is HBsAg positive or their status is unknown, 1 dose of HBIG should also be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Vaccinated with 6 doses of hepatitis B vaccine but documented as a nonresponder to the vaccine:</i> No postexposure vaccination is recommended. If the source patient is HBsAg positive or unknown, administer two doses of HBIG separated by 1 month.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Hemodialysis patients often respond poorly to hepatitis B vaccination; higher vaccine doses or increased number of doses may be required. The anti-HBs (antibody to hepatitis B surface antigen) response of such persons should be tested after they are vaccinated, and those who have not responded should be revaccinated with 1 to 3 additional doses. Patients with chronic renal disease should be vaccinated as early as possible, ideally before they require hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic renal impairment:</i> Infants, Children, and Adolescents: IM: Administer a 3-dose series with subsequent doses at 1 to 2 and 4 to 6 months after the initial dose; repeat dose depending upon annual assessment of hepatitis B surface antigen (anti-HB) level; if anti-HB &lt;10 milliunits/mL administer an additional dose (CDC/ACIP [Mast 2005]; Rangel 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dialysis and predialysis patients (CrCl &lt;60 mL/minute/1.73 m<sup>2</sup>):</i> Infants, Children, and Adolescents: IM: There are no specific ACIP recommendations regarding dosing in dialysis patients; however, some experts suggest that pediatric patients follow standard pediatric schedule; higher doses or additional doses may be required (CDC 2012; CDC/ACIP [Mast 2005]; Neu 2012; Rangel 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recombivax HB (40 mcg/mL dialysis formulation): Limited data available: Children and Adolescents: IM: 0.5 mL/dose (20 mcg) for 3-dose series with subsequent doses at 1 month and 6 months after the first dose. Dosing based on a multicenter trial of 78 pediatric patients (age: 1 to 18 years) using Recombivax-HB (Dialysis formulation) and showed protective levels of antibody occurring in 75% to 97% of pediatric hemodialysis patients using higher dose (Watkins 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &ge;20 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Predialysis patients: Recombivax HB 40 mcg/mL: IM: Administer 1 mL per dose at 0, 1, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dialysis patients: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Engerix-B 20 mcg/mL: Administer 2 mL per dose at 0, 1, 2, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Recombivax HB 40 mcg/mL: Administer 1 mL per dose at 0, 1, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112948\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis patients often respond poorly to hepatitis B vaccination; higher vaccine doses or increased number of doses may be required. The anti-HBs (antibody to hepatitis B surface antigen) response of such persons should be tested after they are vaccinated, and those who have not responded should be revaccinated with 1 to 3 additional doses. Patients with chronic renal disease should be vaccinated as early as possible, ideally before they require hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic renal impairment:</i> Infants, Children, and Adolescents: IM: Administer a 3-dose series with subsequent doses at 1 to 2 and 4 to 6 months after the initial dose; repeat dose depending upon annual assessment of hepatitis B surface antigen (anti-HB) level; if anti-HB &lt;10 milliunits/mL administer an additional dose (CDC/ACIP [Mast 2005]; Rangel 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dialysis and predialysis patients (CrCl &lt;60 mL/minute/1.73 m<sup>2</sup>):</i> Infants, Children, and Adolescents: IM: There are no specific ACIP recommendations regarding dosing in dialysis patients; however, some experts suggest that pediatric patients follow standard pediatric schedule; higher doses or additional doses may be required (CDC 2012; CDC/ACIP [Mast 2005]; Neu 2012; Rangel 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recombivax HB (40 mcg/mL dialysis formulation): Limited data available: Children and Adolescents: IM: 0.5 mL/dose (20 mcg) for 3-dose series with subsequent doses at 1 month and 6 months after the first dose. Dosing based on a multicenter trial of 78 pediatric patients (age: 1 to 18 years) using Recombivax-HB (Dialysis formulation) and showed protective levels of antibody occurring in 75% to 97% of pediatric hemodialysis patients using higher dose (Watkins 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112949\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178987\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=recombinant-hepatitis-b-vaccine-non-adjuvanted-drug-information\" class=\"drug drug_general\">see &quot;Recombinant hepatitis B vaccine (non-adjuvanted): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization:</b> IM: <b>Note:</b> Adult formulations of hepatitis B vaccine products differ by concentration (mcg/mL) but when dosed in terms of volume (mL), the dose of Engerix-B and Recombivax HB are the same (both 1 mL).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunocompetent adults: 1 mL/dose (adult formulation) for 3 total doses administered at 0, 1, and 6 months. <b>Note:</b> Refer to CDC guideline (Mast 2006) for other options. Manufacturer labeling may include alternate immunization schedules.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults with immunocompromising conditions (ACIP [Kim 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Engerix-B 20 mcg/mL: Administer 2 mL per dose at 0, 1, 2, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recombivax HB 40 mcg/mL: Administer 1 mL per dose at 0, 1, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Bombings or similar mass-casualty events:</b> IM: In persons without a reliable history of vaccination against HepB and who have no known contraindications to the vaccine, vaccination should begin within 24 hours (but no later than 7 days) following the event (CDC [Chapman 2008]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Postexposure management of health care personnel (HCP) (CDC [Schillie 2013]):</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Documented vaccine responder:</i> If the HCP has prior documentation of &ge;3 doses of a hepatitis B vaccine and a postvaccination anti-HBs &ge;10 milliunits/mL, then additional hepatitis B vaccine is not needed, regardless of the patients HBsAg status. HCP is considered seroprotected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Unvaccinated or incompletely vaccinated:</i> The primary vaccination series should be completed regardless of the source patients HBsAg status. If the source patient is HBsAg positive or their status is unknown, 1 dose of hepatitis B vaccine and 1 dose of hepatitis B immune globulin (HBIG) should be administered as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Vaccinated with 3 doses of hepatitis B vaccine but postvaccination anti-HBs status is unknown:</i> Test HCP for anti-HBs. If anti-HBs &ge;10 milliunits/mL additional hepatitis B vaccine is not needed. If anti-HBs &lt;10 milliunits/mL, initiate revaccination by administering a single dose of the vaccine and retesting for anti-HBs in 1 to 2 months; if needed 2 additional doses may be given and then retest anti-HBs level. Alternately, administer 3 consecutive doses of the vaccine and then retest anti-HBs level. Minimum dosing intervals are 4 weeks between doses 1 and 2, and 8 weeks between doses 2 and 3; maximum total 6 doses of hepatitis B vaccine (including the original series). If the source patient is HBsAg positive or their status is unknown, 1 dose of HBIG should also be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Vaccinated with 6 doses of hepatitis B vaccine but documented as a nonresponder to the vaccine:</i> No postexposure vaccination is recommended. If the source patient is HBsAg positive or unknown, administer two doses of HBIG separated by 1 month.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991711\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">&ge;20 years:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Predialysis patients: Recombivax HB 40 mcg/mL: Administer 1 mL per dose at 0, 1, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis patients:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Engerix-B 20 mcg/mL: Administer 2 mL per dose at 0, 1, 2, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recombivax HB 40 mcg/mL: Administer 1 mL per dose at 0, 1, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Serologic testing is recommended 1 to 2 months after the final dose of the primary vaccine series and annually to determine the need for booster doses. Persons with anti-HBs concentrations of &lt;10 milliunits/mL should be revaccinated with 3 doses of the vaccine (CDC/ACIP [Mast 2006]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989032\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178967\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, suspension [adult, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Engerix-B: Hepatitis B surface antigen 20 mcg/mL (1 mL) [contains aluminum, yeast protein, may contain natural rubber/natural latex in prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Engerix-B: Hepatitis B surface antigen 20 mcg/mL (1 mL) [contains aluminum, yeast protein; vial]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Recombivax HB: Hepatitis B surface antigen 10 mcg/mL (1 mL) [contains aluminum, natural rubber/natural latex in packaging, yeast protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, suspension [dialysis formulation, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Recombivax HB: Hepatitis B surface antigen 40 mcg/mL (1 mL) [contains aluminum, natural rubber/natural latex in packaging, yeast protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, suspension [pediatric/adolescent, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Engerix-B: Hepatitis B surface antigen 10 mcg/0.5 mL (0.5 mL) [contains aluminum, yeast protein, may contain natural rubber/natural latex in prefilled syringe]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Recombivax HB: Hepatitis B surface antigen 5 mcg/0.5 mL (0.5 mL) [contains aluminum, natural rubber/natural latex in packaging, yeast protein]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178954\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734113\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-b.html&amp;token=tF/G0g1G66lNQera+j9XUDrhwVyBBZjpceOKUtT8GT0aQq8oa/sndGFR2mkrBX5NgDQSGj9LuTrzsrYaiCqjk68AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=12938\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-b.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059216\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Shake well; administer IM into midlateral aspect of the thigh in infants and small children; administer in the deltoid area to older children and adults; not for IV administration. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. Adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]. US law requires that the date of administration; the vaccine manufacturer; lot number of vaccine; and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, hepatitis B vaccine may be administered subcutaneously although lower titers and/or increased incidence of local reactions may result. The ACIP recommends that the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178981\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Refrigerate at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Discard if product has been frozen. The following stability information has also been reported for Engerix-B: May be stored at room temperature for up to 72 hours (Cohen, 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059215\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Active immunization against infection caused by all known subtypes of hepatitis B virus (FDA approved in all ages).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; All neonates weighing &ge;2 kg within 24 hours of birth and neonates weighing &lt;2 kg before hospital discharge (AAP 2017; CDC/ACIP [Mast 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; All infants and children (ACIP [Robinson 2017]; CDC/ACIP [Mast 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; All unvaccinated adults requesting protection from HBV infection (CDC/ACIP [Mast 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; All unvaccinated adults at risk for HBV infection such as those with:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Behavioral risks: Sexually active persons with &gt;1 partner in a 6-month period; persons seeking evaluation or treatment for a sexually transmitted disease; men who have sex with men; injection drug users (CDC/ACIP [Mast 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Occupational risks: Healthcare and public safety workers with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids (CDC/ACIP [Mast 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Medical risks: Persons with end-stage renal disease (including predialysis, hemodialysis, peritoneal dialysis, and home dialysis); persons with HIV infection; persons with chronic liver disease (ACIP [Kim 2017]; CDC/ACIP [Mast 2006]). Adults (19 to 59 years of age) with diabetes mellitus type 1 or type 2 should be vaccinated as soon as possible following diagnosis. Adults &ge;60 years with diabetes mellitus may also be vaccinated at the discretion of their treating clinician based on the likelihood of acquiring HBV infection (CDC/ACIP 60[50] 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Other risks: Household contacts and sex partners of persons with chronic HBV infection; residents and staff of facilities for developmentally disabled persons; international travelers to regions with high or intermediate levels of endemic HBV infection (CDC/ACIP [Mast 2006])</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In addition, the ACIP recommends vaccination for any persons who are wounded in bombings or similar mass casualty events who have penetrating injuries or nonintact skin exposure, or who have contact with mucous membranes (exception - superficial contact with intact skin), and who cannot confirm receipt of a hepatitis B vaccination (CDC [Chapman 2008]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179005\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Engerix-B adult may be confused with Engerix-B pediatric/adolescent</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Recombivax HB may be confused with Comvax</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Recombivax HB may be confused with Recombivax HB Dialysis Formulation</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HepB (hepatitis B vaccine) may be confused with HepA (hepatitis A vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HepB (hepatitis B vaccine) may be confused with Hib (haemophilus b conjugate vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HepB (hepatitis B vaccine) may be confused with HPV4 (human papillomavirus vaccine [quadrivalent]; 4vHPV is the correct abbreviation)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HBV (previously used for hepatitis B vaccine; HepB is correct abbreviation) may be confused with HPV (human papilloma virus vaccine; 2vHPV, 4vHPV, or 9vHPV are the correct abbreviations)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179004\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or online at <a target=\"_blank\" href=\"https://vaers.hhs.gov/esub/index&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD+0my2cUJQ&amp;TOPIC_ID=12938\" target=\"_blank\">https://vaers.hhs.gov/esub/index</a>.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing, hypotension </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Body pain, chills, dizziness, drowsiness, fatigue, headache, insomnia, irritability, malaise, paresthesia, tingling sensation, vertigo </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaphoresis, pruritus, skin rash, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, decreased appetite, diarrhea, dyspepsia, nausea, stomach cramps, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Dysuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Bruising at injection site, erythema at injection site, induration at injection site, injection site nodule, itching at injection site, local soreness/soreness at injection site, pain at injection site, swelling at injection site, tenderness at injection site, warm sensation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, neck pain, neck stiffness, shoulder pain, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Otalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough, pharyngitis, rhinitis, upper respiratory tract infection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever (&ge;37.5&deg;C/100&deg;F)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Acute exacerbations of multiple sclerosis, apnea, Bell's palsy, encephalitis, febrile seizures, Guillain-Barre syndrome, herpes zoster, hypersensitivity reaction, hypoesthesia, increased erythrocyte sedimentation rate, increased liver enzymes, keratitis, lupus-like syndrome, migraine, multiple sclerosis, myelitis, neuropathy, optic neuritis, paralysis, paresis, periarteritis nodosa, peripheral neuropathy, purpura, radiculopathy, seizure, serum-sickness like reaction (may be delayed days to weeks), Stevens-Johnson syndrome, syncope, systemic lupus erythematosus, tachycardia, thrombocytopenia, transverse myelitis, uveitis, vasculitis, visual disturbances</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178973\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe allergic or hypersensitivity reaction to yeast, hepatitis B vaccine, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling):  Known hypersensitivity to any component of the formulation; severe febrile illness.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178958\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]). Canadian labeling contraindicates use of the vaccine in patients with severe febrile illness.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple sclerosis: Postmarketing reports of multiple sclerosis (MS) exacerbations have been reported; however, clinical studies indicate no association between vaccination and MS.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients &gt;60 years of age may have lower response rates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]). However, infants born to HBsAg-negative mothers and weighing &lt;2 kg at birth should have the initial dose deferred up to 30 days of chronological age or until hospital discharge. If the mothers HBsAg status at delivery is unknown or positive, hepatitis B vaccine and hepatitis B immune globulin should be administered within 12 hours of life and the first dose of the vaccine should not be counted as part of the vaccine series. Apnea has been reported following IM vaccine administration in premature infants; consider clinical status implications (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (CDC/ACIP [Kim 2017]; CDC/ACIP [Robinson 2017]). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available in the IDSA guidelines (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and is improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]). Due to the long incubation period for hepatitis, unrecognized hepatitis B infection may be present prior to vaccination; immunization may not prevent infection in these patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299442\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178962\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12938&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178964\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178977\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. The ACIP recommends HBsAg testing for all pregnant women. Based on limited data, there is no apparent risk to the fetus when the hepatitis B vaccine is administered during pregnancy. Pregnancy itself is not a contraindication to vaccination; vaccination should be considered if otherwise indicated (CDC/ACIP [Mast 2006]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059211\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">HBsAg and antibodies to HBsAg (anti-HBs) should be tested in infants born to mothers positive for HBsAg when they are 9 to 18 months of age (eg, next well child visit) or 1 to 2 months after completion of the hepatitis B vaccination series (ACIP [Robinson 2016]); annual anti-HB in dialysis patients. Vaccination at the time of HBsAg testing: For persons in whom vaccination is recommended, the first dose of hepatitis B vaccine can be given after blood is drawn to test for HBsAg. Observe for syncope for 15 minutes following administration (NCIRD/ACIP 2011). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178957\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Recombinant hepatitis B vaccine is a noninfectious subunit viral vaccine, which confers active immunity via formation of antihepatitis B antibodies. The vaccine is derived from hepatitis B surface antigen (HBsAg) produced through recombinant DNA techniques from yeast cells. The portion of the hepatitis B gene which codes for HBsAg is cloned into yeast, which is then cultured to produce hepatitis B vaccine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178972\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efficacy:  Postvaccination seroprotection is found in ~95% of healthy infants, ~92% of health care personnel &lt;40 years of age, and ~84% of health care personnel &ge;40 years of age (CDC [Schillie 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Following a 3-dose series in pediatric patients, up to 50% of patients will have low or undetectable anti-HB antibody 5 to 15 years postvaccination. However, anamnestic increases in anti-HB have been shown up to 23 years later suggesting a lifelong immune memory response (CDC/ACIP [Mast 2005]; CDC/ACIP [Mast 2006]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10278561\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">With use of hepatitis B vaccine, hepatitis D should also be prevented since delta virus replicates only in presence of HBV infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178976\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Injection</b> (Engerix-B Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/0.5 mL (0.5 mL): $24.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg/mL (1 mL): $55.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Engerix-B Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/0.5 mL (0.5 mL): $27.51</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg/mL (1 mL): $62.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Recombivax HB Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg/0.5 mL (0.5 mL): $28.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/mL (1 mL): $74.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg/mL (1 mL): $199.10</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178978\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amvax B (PH);</li>\n      <li>Bio-Hep-B (IL);</li>\n      <li>Engerix B (VN);</li>\n      <li>Engerix-B (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CL, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GR, GT, GY, HK, HN, HU, ID, IE, IN, IS, IT, JM, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PK, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SR, SV, TH, TR, TT, TW, UA, UY, VE, ZA);</li>\n      <li>Fendrix (BE, BG, CZ, EE, ES, FR, GB, GR, HR, IE, IT, MT, NL, NO, PL, PT, RO, SE, SK, TR);</li>\n      <li>H-B-Vax II (AT, AU, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GR, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR, TW);</li>\n      <li>HB-Vax (AE, QA);</li>\n      <li>HBvaxPRO (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, IE, IT, MT, NL, NO, NZ, PL, PT, RU, SE, SK, TR);</li>\n      <li>HBvaxPro (ES);</li>\n      <li>Hepavax Gene (CO);</li>\n      <li>Shanvac-B (PH, TW);</li>\n      <li>Temrevac-HB (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP); Committee on Infectious Diseases; Committee on Fetus and Newborn. Elimination of perinatal hepatitis B: providing the first vaccine dose within 24 hours of birth. <i>Pediatrics</i>. 2017;140(3):e20171870.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/28847980/pubmed\" target=\"_blank\" id=\"28847980\">28847980</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease, summarized from recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention website. Available at <a href=\"http://www.cdc.gov/vaccines/pubs/downloads/dialysis-guide-2012.pdf\" target=\"_blank\">http://www.cdc.gov/vaccines/pubs/downloads/dialysis-guide-2012.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2011;60(50):1709-1711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/22189894/pubmed\" target=\"_blank\" id=\"22189894\">22189894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman LE, Sullivent EE, Grohskopf LA, et al. Centers for Disease Control and Prevention (CDC). Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events &minus; United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC). <i>MMWR Recomm Rep</i>. 2008;57(RR-6):1-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/18668022/pubmed\" target=\"_blank\" id=\"18668022\">18668022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, Berkovits E, Goldman WM. Room-temperature storage of medications labeled for refrigeration. <i>Am J Health-Syst Pharm</i>. 2007;64(16):1711-1715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Engerix-B (hepatitis B vaccine [recombinant]) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents [published corrections appear in MMWR Recomm Rep. 2006;56(48):1267; MMWR Recomm Rep. 2007;55(6):158-159]. <i>MMWR Recomm Rep</i>. 2005;54(RR-16):1-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/16371945/pubmed\" target=\"_blank\" id=\"16371945\">16371945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mast EE, Weinbaum CM, Fiore AE, et al. Advisory Committee on Immunization Practices (ACIP). Advisory Committee on Immunization Practices (ACIP); Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults [published correction appears in MMWR Morb Mortal Wkly Rep. 2007;56(42):1114]. <i>MMWR Recomm Rep</i>. 2006;54(RR-16):1-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/17159833/pubmed\" target=\"_blank\" id=\"17159833\">17159833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Center for Immunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2011;60(2):1-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/21293327 /pubmed\" target=\"_blank\" id=\"21293327 \">21293327 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neu AM. Immunizations in children with chronic kidney disease. <i>Pediatr Nephrol</i>. 2012;27(8):1257-1263.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/22048175/pubmed\" target=\"_blank\" id=\"22048175\">22048175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. <i>Semin Dial</i>. 2000;13(2):101-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/10795113/pubmed\" target=\"_blank\" id=\"10795113\">10795113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Recombivax HB (hepatitis b vaccine [recombinant]) [prescribing information]. Whitehouse Station NJ: Merck &amp; Co., Inc; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years - United States, 2016. <i>MMWR Morb Mortal Wkly Rep</i>. 2016;65(4):86-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/26845283 /pubmed\" target=\"_blank\" id=\"26845283 \">26845283 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saari TN, American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. <i>Pediatrics</i>. 2003;112(1 Pt 1):193-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/12837889/pubmed\" target=\"_blank\" id=\"12837889\">12837889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schillie S, Murphy TV, Sawyer M, et al. Centers for Disease Control and Prevention (CDC). CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. <i>MMWR Recomm Rep</i>. 2013;62(RR-10):1-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/24352112/pubmed\" target=\"_blank\" id=\"24352112\">24352112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watkins SL, Alexander SR, Brewer ED, et al. Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failure. <i>Am J Kidney Dis</i>. 2002;40(2):365-372.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hepatitis-b-vaccine-non-adjuvanted-pediatric-drug-information/abstract-text/12148110/pubmed\" target=\"_blank\" id=\"12148110\">12148110</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12938 Version 107.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178984\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F178985\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059212\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442600\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1059206\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112948\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112949\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F178987\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991711\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989032\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178967\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F178954\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734113\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059216\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F178981\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059215\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F179005\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F179004\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178973\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F178958\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299442\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F178962\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F178964\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F178977\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1059211\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F178957\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F178972\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10278561\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F178976\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F178978\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12938|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=recombinant-hepatitis-b-vaccine-non-adjuvanted-drug-information\" class=\"drug drug_general\">Recombinant hepatitis B vaccine (non-adjuvanted): Drug information</a></li><li><a href=\"topic.htm?path=recombinant-hepatitis-b-vaccine-non-adjuvanted-patient-drug-information\" class=\"drug drug_patient\">Recombinant hepatitis B vaccine (non-adjuvanted): Patient drug information</a></li></ul></div></div>","javascript":null}